Vicore’s Phase 2b IPF Trial Clears Futility Review

An independent data monitoring committee recommended continuing the fully enrolled 378-patient ASPIRE trial of buloxibutid without modification after a planned futility analysis; no safety concerns were raised. Topline results are targeted for mid-2027.